Antibiotic resistance trends were examined for Shigella species, nontyphoidal Salmonella species, enterotoxigenic Escherichia coli (ETEC), and Campylobacter species isolates from indigenous persons and travelers in Thailand for up to 15 years. Resistance to trimethoprim-sulfamethoxazole was found in ú90% of Shigella and 40% of ETEC and nontyphoidal Salmonella isolates. Resistance to nalidixic acid was found in 97% -100% of Shigella dysenteriae 1 strains isolated between 1992 and 1995. Ciprofloxacin resistance was detected in 1% of ETEC isolates in 1994 and 1995 and in one of 349 nontyphoidal Salmonella isolates in 1995. Ciprofloxacin resistance among Campylobacter species increased from zero before 1991 to 84% in 1995 (P õ .0001). Azithromycin resistance was found in 7% -15% of Campylobacter isolates in 1994 and 1995, as well as 15% of ETEC and 3% of Salmonella isolates in 1995. Enteric pathogens in Thailand have developed resistance to virtually all antibiotics routinely used in the treatment of diarrhea, as well as the newer fluoroquinolone and macrolide classes of drugs.
The progressive increase in antimicrobial resistance among
The Armed Forces Research Institute of Medical Sciences, in Bangkok, has been coordinating numerous studies on the enteric pathogens in developing countries is becoming a critical area of concern. Antibiotic treatment is indicated for dysentery etiology, epidemiology, and treatment of diarrheal diseases in Thailand for many years [6 -11] . Since 1981, antibiotic suscepcaused by Shigella species, for instance, and shigellae are becoming increasingly resistant to most antimicrobial agents tibility of bacterial isolates, including Shigella, ETEC, and nontyphoidal Salmonella from patients with diarrhea, have been commonly used in the treatment of diarrhea [1] . The most virulent Shigella species, Shigella dysenteriae type 1, is also tested against the most common antibiotics, including ampicillin, tetracycline, chloramphenicol, and trimethoprim-sulfathe most resistant of the species [1, 2] . As another example, the emergence in Thailand of Campylobacter species that are methoxazole (TMP-SMZ). For at least 5 years, testing of these pathogens against nalidixic acid and fluoroquinolones has also resistant to ciprofloxacin as well as azithromycin [3] has threatened to undermine the effective treatment of travelers' diarrhea been conducted. In addition, data have been collected in recent years on azithromycin resistance among these enteric pathoin this region.
Despite the seriousness of the problem, surveillance for antigens, and the emergence of fluoroquinolone and azithromycin resistance in Campylobacter species has been monitored. A biotic-resistant enteric pathogens in developing countries has not been well reported. Longitudinal trends spanning more than review of these data offers insight into the antibiotic resistance trends for the most common bacterial causes of diarrhea over a few years are not readily available, and there are limited data on newer classes of antibiotics, such as quinolones and a 15-year period in an Asian country. macrolides. While there are relatively more data published for Shigella species and Vibrio cholerae [1, 4, 5] , little is known Methods about the longitudinal trends in susceptibility of other common enteric pathogens, including enterotoxigenic Escherichia coli Source of isolates. Antibiotic susceptibility data were rou-(ETEC), Campylobacter species, and nontyphoidal Salmonella tinely compiled on Shigella, nontyphoidal Salmonella, and species.
ETEC bacteria isolated from stool specimens collected from indigenous persons (mostly children) involved in numerous studies of community-acquired diarrhea between 1981 and 1995. Populations included native Thais, predominantly chil- Resistance to TMP-SMZ climbed from õ10% in the early for fluoroquinolone and azithromycin resistance among 1980s to ú90% for Shigella isolates and Ç40% for ETEC and Campylobacter species isolated from U.S. military personnel nontyphoidal Salmonella isolates in the later years of surveiland to confirm resistance detected initially by disk susceptibillance (figure 2). Nalidixic acid resistance among these pathoity testing among Shigella, ETEC, and Salmonella isolated gens was first recognized in the early 1990s and is now found from Thais. In order to evaluate resistance to azithromycin in 1% -2% of isolates of ETEC and Shigella other than among Shigella, ETEC, and Salmonella species, isolates from S. dysenteriae type 1. The percentage of nontyphoidal Salmo-U.S. military personnel and from a randomly selected sample nella isolates resistant to nalidixic acid rose from õ2% in of isolates from Thai patients in 1995 were tested against 1991 -1992 to 4% in 1993 -1994 (57) 48 (84) 4 (7) NOTE. NT Å not tested. * All data based on MIC agar dilution method [13, 14] . Resistance was Figure 1 . Percentage of resistance to ampicillin among isolates of defined as §4 mg/mL for ciprofloxacin, §16 mg/mL for norfloxacin, and §8
Shigella species other than S. dysenteriae type 1 (*), enterotoxigenic mg/mL for azithromycin.
Escherichia coli (l), and nontyphoidal Salmonella species (/) recov- † Isolates from 1987, 1990, 1993 , and 1995 were tested against ciprofloxacin;
ered from indigenous persons in Thailand, 1981 Thailand, -1995 .
isolates from 1994 were tested against norfloxacin (x 2 for trend, P õ .0001).
1,012 Shigella isolates (other than S. dysenteriae type 1), 125 were tested for azithromycin resistance by both disk diffusion S. dysenteriae type 1 isolates, 484 ETEC isolates, and 1,036
and MIC agar dilution methods. All Shigella isolates tested nontyphoidal Salmonella isolates were tested for resistance to were susceptible to this antibiotic. Among the 40 ETEC isociprofloxacin by the disk diffusion method. All Shigella isolates, six (15%) were resistant to azithromycin. Among the lates, including nalidixic acid -resistant S. dysenteriae type 1, 58 Salmonella isolates, two (3%) were resistant to this antibiwere susceptible to ciprofloxacin. Among ETEC isolates, those otic. For all of the resistant ETEC and Salmonella isolates, from 1991 -1993 were uniformly susceptible to ciprofloxacin, MICs of azithromycin were ú64 mg/mL (resistance defined whereas 2 (1%) of 241 ETEC isolates from 1994 and 1995 as §8 mg/mL). were found to be resistant (1 of 153 tested in 1994 and 1 of
Resistance of Campylobacter isolates from travelers to flu-88 tested in 1995). For both of these isolates the MIC was oroquinolones and azithromycin. Campylobacter isolates confirmed to be high (ú32 mg/mL, with §4 mg/mL defined from indigenous persons in Thailand were not routinely tested as resistant). Of 349 nontyphoidal Salmonella isolates tested for antibiotic resistance during the study period. However, after in 1995, 1 (0.3%) was resistant to ciprofloxacin (MIC, 4.0
Campylobacter was identified as the leading cause of diarrhea mg/mL), whereas all Salmonella isolates tested from the period among U.S. troops deployed to Thailand in 1987 [15] , Campy-1991 -1994 (n Å 687) were susceptible to this antibiotic.
lobacter isolates from U.S. troops with diarrhea were tested 1995 Survey for azithromycin resistance among Shigella, routinely for resistance to fluoroquinolones (either ciprofloxa-ETEC, and Salmonella isolates. A total of 33 Shigella isocin or norfloxacin) and, in the later years, to azithromycin as lates, 40 ETEC isolates, and 58 Salmonella isolates from 1995 well (table 2) . During military exercises in 1987 and 1990, Campylobacter isolates were uniformly susceptible to ciprofloxacin. No data are available from 1991 and 1992. In 1993, 40% of isolates were found to be resistant to ciprofloxacin, and by 1995 fluoroquinolone resistance had risen to 84% (x 2 for trend, P õ .0001; table 2). Azithromycin resistance was found in 7%-15% of Campylobacter isolates from 1994 and 1995, while all Campylobacter isolates from 1993 were susceptible to this antibiotic (table 2). All Campylobacter isolates that were resistant to azithromycin were also resistant to ciprofloxacin. treat diarrhea because of their low cost and ready availability 7% -15% of Campylobacter isolates recovered in 1994 and 1995 were resistant to azithromycin. [1, 16] . This study confirms that the first three of these antibiotics no longer have a role in the treatment of noncholera diar-
Discussion
The current study also suggests that resistance to azithromycin may soon restrict the use of this antibiotic for treatment rheal disease in Thailand. High rates of resistance of enteric pathogens to ampicillin and tetracycline (as well as chloramagainst enteric pathogens other than Campylobacter. Results of both disk diffusion and MIC tests show that 15% of ETEC phenicol and sulfa) have remained relatively constant over the last 15 years. Resistance to TMP-SMZ emerged in the early isolates and 3% of Salmonella isolates that were tested in 1995 were resistant to this antibiotic. Since azithromycin is one of 1980s and is now found in ú90% of Shigella isolates and in Ç40% of ETEC and nontyphoidal Salmonella isolates.
the few available alternatives to fluoroquinolones, the development of resistance to this antibiotic among ETEC and SalmoThe 1990s have been notable for the emergence of resistance among enteric pathogens to nalidixic acid and fluoroquinonella as well as Campylobacter species may have serious clinical implications, particularly for travelers, for whom antibiotic lones. Nalidixic acid resistance is now found in 1% -2% of isolates of ETEC and Shigella other than S. dysenteriae type treatment of diarrhea is routinely indicated. Further surveillance for azithromycin resistance among the different enteric patho-1 in Thailand. Nalidixic acid -resistant S. dysenteriae type 1 was first reported from Thailand in 1992 [17] . By 1993, the gens is indicated. One potential limitation of this study is that isolates were epidemic clone had developed resistance to all commonly prescribed antibiotics, including TMP-SMZ, leaving the expensive obtained from various (indigenous and U.S. military) populations in different locations in Thailand, rather than from one fluoroquinolone class of antibiotics and azithromycin as the only available alternatives. An identical pattern of panresispopulation systematically studied over the 15-year period. However, it remains likely that the general trends documented tance among S. dysenteriae type 1 isolates has been observed in other regions of the world [2, 4] . Among nontyphoidal Salin this study are representative of the overall resistance trends for endemic diarrheal pathogens in the region. Since S. dysenmonella isolates, resistance to nalidixic acid increased from õ2% in 1991 to nearly 9% in 1995.
teriae type 1 caused specific localized epidemics, it was important to analyze these isolates separately. Fluoroquinolone resistance has still not been documented among Shigella species, including nalidixic acid-resistant Systematic surveillance and timely reporting of antibiotic resistance patterns among enteric pathogens from different re-S. dysenteriae type 1 in Thailand. In the current study, however, resistance to ciprofloxacin was detected in a few of the other gions of the world should become a high priority. While computerized data systems such as WHONET are being developed, enteric bacterial species, beginning in 1994. Before 1994, ETEC and Salmonella species were uniformly susceptible to ciprofloxathere are enormous problems in implementing such systems on a global basis [20] . It is important to keep in mind that cin. Among ETEC isolates tested in 1994 and 1995, 1% in each year were found to be resistant to this antibiotic. A single cithe principle purpose of monitoring antibiotic resistance trends among enteric pathogens is to provide clinicians with data that profloxacin-resistant isolate of Salmonella was detected in 1995. It will be important to continue to monitor fluoroquinolone-resiscan be used to select appropriate treatment regimens. Surveillance should emphasize antibiotics that are being used routinely tance trends in Thailand over time, as this antibiotic is increasingly used as the first-line agent for the treatment of diarrhea.
for the treatment of diarrhea, as well as any potential alternatives that may be available, such as fluoroquinolones and Among Campylobacter isolates from adult travelers in Thailand, ciprofloxacin resistance is now a major problem. This study highlights the need to develop newer classes of antibiotics to treat diarrheal disease, as well as the need for be resistant to ciprofloxacin, and by 1995 this rate had risen to 84%. The lack of alternative regimens to treat campylobacter alternative strategies such as enteric vaccines. Although vaccines are being developed to protect against the major causes infections is of major concern. In a double-blind study in 1993, azithromycin was shown to provide an equally efficacious alterof bacterial diarrhea, including V. cholerae, ETEC, and Shigella and Campylobacter species, it will likely be many years before native to ciprofloxacin for the treatment of campylobacter infections among U.S. troops [19] . However, by 1994, resistance vaccines are available that are efficacious against the large number of different serotypes of these enteric bacteria. A conto azithromycin was documented [3] . This study confirmed that / 9c46$$fe19 01-08- 
